» Articles » PMID: 34359778

A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma

Abstract

Background: Multiple myeloma bone disease (MMBD) constitutes a common and severe complication of multiple myeloma (MM), impacting the quality of life and survival. We evaluated the clinical value of a panel of 19 miRNAs associated with osteoporosis in MMBD.

Methods: miRNAs were isolated from the plasma of 62 newly diagnosed MM patients with or without MMBD. First-strand cDNA was synthesized, and relative quantification was performed using qPCR. Lastly, we carried out extensive biostatistical analysis.

Results: Circulating levels of let-7b-5p, miR-143-3p, miR-17-5p, miR-214-3p, and miR-335-5p were significantly higher in the blood plasma of MM patients with MMBD compared to those without. Receiver operating characteristic curve and logistic regression analyses showed that these miRNAs could accurately predict MMBD. Furthermore, a standalone multi-miRNA-based logistic regression model exhibited the best predictive potential regarding MMBD. Two of those miRNAs also have a prognostic role in MM since survival analysis indicated that lower circulating levels of both let-7b-5p and miR-335-5p were associated with significantly worse progression-free survival, independently of the established prognostic factors.

Conclusions: Our study proposes a miRNA signature to facilitate MMBD diagnosis, especially in ambiguous cases. Moreover, we provide evidence of the prognostic role of let-7b-5p and miR-335-5p as non-invasive prognostic biomarkers in MM.

Citing Articles

Adherence to the evidence-based recommendations in managing bone health, pain, and mobility of patients with multiple myeloma: a mixed method in the Palestinian healthcare system.

Shawahna R, Amer R, Salameh H, Shawahna A, Aljondy M, Zain-Aldain M BMC Cancer. 2024; 24(1):301.

PMID: 38443861 PMC: 10916152. DOI: 10.1186/s12885-024-12024-z.


Novel Developments in the Treatment of Multiple Myeloma-Associated Bone Disease.

Johansen M, Levring M, Stokbro K, Diaz-delCastillo M, Khan A, Wickstroem L Cancers (Basel). 2023; 15(23).

PMID: 38067289 PMC: 10705210. DOI: 10.3390/cancers15235585.


Circulating and extracellular vesicle-derived microRNAs as biomarkers in bone-related diseases.

Huber J, Longaker M, Quarto N Front Endocrinol (Lausanne). 2023; 14:1168898.

PMID: 37293498 PMC: 10244776. DOI: 10.3389/fendo.2023.1168898.


miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myeloma.

Papadimitriou M, Soureas K, Papanota A, Tsiakanikas P, Adamopoulos P, Ntanasis-Stathopoulos I J Transl Med. 2023; 21(1):245.

PMID: 37024879 PMC: 10080848. DOI: 10.1186/s12967-023-04034-5.


The Relationship between Serum miRNAs and Early Mortality in Multiple Myeloma Patients Treated with Bortezomib-Based Regimens.

Pula A, Robak P, Jarych D, Mikulski D, Misiewicz M, Drozdz I Int J Mol Sci. 2023; 24(3).

PMID: 36769265 PMC: 9917942. DOI: 10.3390/ijms24032938.


References
1.
Kocijan R, Muschitz C, Geiger E, Skalicky S, Baierl A, Dormann R . Circulating microRNA Signatures in Patients With Idiopathic and Postmenopausal Osteoporosis and Fragility Fractures. J Clin Endocrinol Metab. 2016; 101(11):4125-4134. DOI: 10.1210/jc.2016-2365. View

2.
Hillengass J, Usmani S, Rajkumar S, Durie B, Mateos M, Lonial S . International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019; 20(6):e302-e312. DOI: 10.1016/S1470-2045(19)30309-2. View

3.
Wu M, Chen G, Li Y . TGF-β and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease. Bone Res. 2016; 4:16009. PMC: 4985055. DOI: 10.1038/boneres.2016.9. View

4.
Zarecki P, Hackl M, Grillari J, Debono M, Eastell R . Serum microRNAs as novel biomarkers for osteoporotic vertebral fractures. Bone. 2019; 130:115105. DOI: 10.1016/j.bone.2019.115105. View

5.
Sul O, Rajasekaran M, Park H, Suh J, Choi H . MicroRNA-29b Enhances Osteoclast Survival by Targeting BCL-2-Modifying Factor after Lipopolysaccharide Stimulation. Oxid Med Cell Longev. 2019; 2019:6018180. PMC: 6481009. DOI: 10.1155/2019/6018180. View